

Prof. Dr. Klaus-Michael Debatin

Department: Molecular Oncology

CV:

KLAUS-MICHAEL DEBATIN

Prof. Dr. med.

Personal

Date of birth: December 6, 1952

Place of birth: Karlsruhe, Germany

Academic Education and Appointments

1971

Final exams, Humanistic Secondary School, Karlsruhe

1971 - 1978

Medical school, Universities of Ulm, Freiburg and Heidelberg

1976 - 1979

PhD thesis, Institute for Immunology, University of Heidelberg (Prof. Dr. K. Rother)

1978

MD degree and medical license

1979

Doctorate degree (PhD: magna cum laude), University of Heidelberg

1979 - 1982

Research fellow, Institute of Immunology

University of Heidelberg and Max-Planck-Institute for Immunobiology, Freiburg

1980 - 1981

Immunology fellowship, German Research Council (DFG) University of Heidelberg, MPI Freiburg

1981 - 1989

Training for specialist in pediatrics, University Children's Hospital, Heidelberg

1983 - 1990

Clinical fellow and research fellow (Oncology/Immunology Section)

University Children's Hospital, Heidelberg

1989

Board certification in pediatrics

1984 - 1990

Guest scientist, Division of Immunogenetics

German Cancer Research Center, Heidelberg

1986

Visiting scientist, Dana Farber Cancer Institute, Boston and Memorial Sloan-Kettering Cancer Center, New York

1987 - 1990

Head of Laboratory of Immunology and Hematology, University Children's Hospital, Heidelberg and Acting Head, Oncology/Immunology Section, University Children's Hospital, Heidelberg

1989

Visiting scientist, National Cancer Institute (Metabolism Branch, Dr. T.A. Waldmann), Bethesda, USA

1989

Visiting scientist, Institute Mario Negri and Section Hematology, University Children's Hospital, Milan

1990

Habilitation in pediatrics, University of Heidelberg

1990 - 1991

Research fellow of the German Research Council (DFG) and "Fogarty fellow", National Cancer Institute Bethesda, USA

1991 - 1994

Heisenberg fellow of the German Research Council (DFG)

- National Cancer Institute, USA (Fogarty Fellow)

- German Cancer Research Center, Heidelberg

- Hôpital Necker, Paris

1994 - 1997

Head, Hematology/Oncology Section, University Children's Hospital, Heidelberg

1995 - 2004

Head, Division of Molecular Oncology, German Cancer Research Center

since 1997

Full professor of pediatrics, University of Ulm

since 1997

Chairman, Department of Pediatrics, University Medical Center Ulm and
Physician-in-chief of the University Children's Hospital Ulm

2002 - 2004

Vice Dean, Medical Faculty, Ulm University

2004 - 2010

Dean, Medical Faculty, Ulm University

2010 – 02/2014

Vice President Medicine, Ulm University

2010 – 09/2013

Deputy Medical Director, University Medical Center Ulm

10/2013 – 02/2015

CEO and Medical Director, University Medical Center Ulm

since 03/2015

CEO Centre for Rare Diseases (Zentrum für Seltene Erkrankungen-ZSE),
University Medical Center Ulm

since 10/2015

Vice President, Ulm University

Publications

(This is not a complete list of publications, but only a selection of the major ones.)

Trauth, BC, Klas, C, Peters, AMJ, Matzku, S, Möller, P, Falk, W, Debatin, KM, Krammer, PH, 1989. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 245, 301-305.

Debatin, KM, Goldmann, CK, Bamford, R, Waldmann, TA, Krammer, PH (1990) Monoclonal antibody-mediated apoptosis in adult T cell leukemia. *Lancet* 335, 497-500.

Dhein, J, Walczak, H, Bäuml, C, Debatin, KM, Krammer, PH, 1995. Autocrine T-cell suicide mediated by APO-1/Fas (CD95). *Nature* 373, 438-441.

Rieux-Laucat, F, Le Deist, F, Hivroz, C, Roberts, IAG, Debatin, KM, Fischer, A, De Villartay, JP, 1995. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. *Science* 268, 1347-1349.

Friesen, C, Herr, I, Krammer, PH, Debatin, KM, 1996. Involvement of the CD95 (APO-1/Fas) receptor/ ligand system in drug induced apoptosis in leukemia cell. *Nat. Med.* 2, 574-577.

Fulda, S, Wick, W, Weller, M, Debatin, KM, 2002. Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. *Nat. Med.* 8(8), 808-815.

Meyer, LH, Karawajew, L, Schrappe, E, Ludwig, WD, Stahnke, K, Debatin, KM, 2006. Cytochrome c related caspase activation determines treatment response and relapse in childhood B-precursor ALL. *Blood* 107(11), 4524-3.

Opel, D, Poremba, C, Simon, T, Debatin, KM, Fulda, S, 2007. Activation of Akt predicts poor outcome in neuroblastoma. *Cancer Research* 67(2), 735-745.

Meyer, LH, Queudeville, M, Eckhoff, SM, Creutzig, U, Reinhardt, D, Karawajew, L, Ludwig, WD, Stahnke, K, Debatin, KM, 2008. Intact apoptosis signaling in myeloid leukaemia cells determines treatment outcome in childhood AML. *Blood* 111(5), 2899-2903.

Vogler, M, Walczak, H, Stadel, D, Genze, F, Haas, T, Jovanovic, M, Gschwend, J, Simmet, T, Debatin, KM, Fulda, S, 2008. Targeting XIAP bypasses Bcl-2-mediated resistance to TRAIL and cooperates with TRAIL to suppress pancreatic cancer growth in vitro and in vivo. *Cancer Research* 68(19), 7956-7965.

Fakler, M, Loeder, S, Vogler, M, Schneider, K, Jeremias, I, Debatin, KM, Fulda, S, 2009. Small molecule XIAP inhibitors cooperate with TRAIL to induce apoptosis in childhood acute leukemia cells and overcome Bcl-2-mediated resistance. *Blood* 113(8), 1710-1722.

Strauss, G, Lindquist, JA, Arhel, N, Felder, E, Karl, S, Haas, T, Fulda, S, Walczak, H, Kirchhoff, F, Debatin, KM, 2009. CD95 co-stimulation blocks activation of naive T cells by inhibiting T cell receptor signaling. *Journal of Experimental Medicine* 206, 1379-93.

Meyer, LH, Eckhoff, SM, Queudeville, M, Kraus, JM, Giordan, M, Stursberg, J, Zangrando, A, Vendramini, E, Möricke, A, Zimmermann, M, Schrauder, A, Lahr, G, Holzmann, K, Schrappe, M, Basso, G, Stahnke, K, Kestler, HA, te Kronnie, G, Debatin, KM, 2011. Early relapse in pediatric ALL is identified by Time To Leukemia (TTL) in NOD/SCID mice and is characterized by a gene signature involving survival pathways. *Cancer Cell* 19(2), 206-17.

Queudeville, M, Seyfried, F, Eckhoff, SM, Trentin, L, Ulrich, S, Schirmer, M, Debatin, KM, Meyer, LH, 2012. Rapid engraftment of human ALL in NOD/SCID mice involves deficient apoptosis signaling. *Cell Death Dis* 3, e364.

Hartmann, N, Messmann, JJ, Leithäuser, F, Weiswange, M, Kluge, M, Fricke, H, Debatin, KM, Strauss, G, 2013. Recombinant CD95-Fc (APG101) prevents graft-versus-host disease in mice without disabling antitumor cytotoxicity and T-cell functions. *Blood* 121(3):556-65.

Wabitsch, M, Funcke, JB, Lennerz, B, Kuhnle-Krahl, U, Lahr, G, Debatin, KM, Vatter, P, Gierschik, P, Moepps, B, Fischer-Posovszky, P, 2015. Biologically inactive leptin and early-onset extreme obesity. *N Engl J Med* 372 (1), 48-54.

Münch, V, Trentin, L, Herzig, J, Demir, S, Seyfried, F, Kraus, JM, Kestler, HA, Köhler, R, Barth, TFE, Te Kronnie, G, Debatin, KM, Meyer, LH, 2017. Central nervous system involvement in acute lymphoblastic 2

leukemia is mediated by vascular endothelial growth factor. *Blood* 130 (5), 643-654.

Trentin, L, Queudeville, M, Eckhoff, SM, Hasan, MN, Münch, V, Boldrin, E, Seyfried, F, Enzenmüller, S, Debatin, KM*, Meyer, LH*, 2018. Leukemia reconstitution in vivo is driven by cells in early cell cycle and low metabolic state. *Haematologica* 103(6):1008-1017

Dorneburg, C, Fischer, M, Barth, TFE, Mueller-Klieser, W, Hero, B, Gecht, J, Carter, DR, De Preter, K, Mayer, B, Christner, L, Speleman, F, Marshall, GM, Debatin, KM, Beltinger, C, 2018. LDHA in neuroblastoma is associated with poor outcome and its depletion decreases neuroblastoma growth independent of aerobic glycolysis. *Clin Cancer Res* 24 (22), 5772-5783.

Demir, S, Boldrin, E, Sun, Q, Hampp, S, Tausch, E, Eckert, C, Ebinger, M, Handgretinger, R, Te Kronnie, G, Wiesmüller, L, Stilgenbauer, S, Selivanova, G, Debatin, KM, Meyer, LH, 2019. Therapeutic targeting of mutant p53 in pediatric acute lymphoblastic leukemia. *Haematologica* [ePub ahead of print].

Awards

1991

Kind Philipp Award of the Society for Pediatric Oncology and Hematology

1996

"Presidential Lecture", 12th Meeting of the International Histiocyte Society, Wien

1997

SmithKline Beecham Award for Clinical Research

1998

Wilhelm-Warner-Preis für Krebsforschung

2001

Full member of the Gesellschaft für Naturforscher Leopoldina, Nationale Akademie der Wissenschaften

2002

Deutscher Krebspreis

2005

Full member of the Heidelberger Akademie der Wissenschaften

2007

European Union Descartes Research Prize 2006

2008

ASM Prize 2008 (British Society for Haematology)

2011

Career Award, European Cell Death Organisation (ECDO)

2011

Full member of the European Academy of Cancer Sciences (ECCO)

2012

Deutsche Krebshilfe Preis 2011